Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
(1) Aim: Non-alcoholic fatty liver disease (NAFLD) is a prevalent disease worldwide. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) bear anti-inflammatory action and can ameliorate hyperlipidemia. We wish to appraise the effects of n-3 PUFAs supplement on NAFLD. (2) Methods: We searched CENTRAL, Embase, and MEDLINE on 29 March 2020 for randomized control trials (RCTs) on the effects of n-3 PUFAs supplementation in treating NAFLD. The Cochrane Collaboration’s tool was used to assess the risk of bias of included RCTs. (3) Results: We included 22 RCTs with 1366 participants. The risk of bias of included RCTs was generally low or unclear. n-3 PUFAs supplementation significantly reduced liver fat compared with placebo (pooled risk ratio 1.52; 95% confidence interval (CI) 1.09 to 2.13). n-3 PUFAs supplementation also significantly improved the levels of triglyceride, total cholesterol, high-density lipoprotein, and body-mass index, with pooled mean difference and 95% CI being −28.57 (−40.81 to −16.33), −7.82 (−14.86 to −0.79), 3.55 (1.38 to 5.73), and −0.46 (−0.84 to −0.08), respectively. (4) Conclusions: The current evidence supports the effects of n-3 PUFAs supplementation in improving fatty liver. n-3 PUFAs supplementation may also improve blood lipid levels and obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 5×
“Because high levels of fasting insulin and associated hepatic insulin resistance are usually present in NAFLD patients, they are also susceptible to T2DM.”
BackgroundInfluentialLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 1×
“NAFLD patients have increased mortality with increasing stages of liver fibrosis [6].”
BackgroundOmega-3 polyunsaturated fatty acids and their health benefits
Shahidi, F., & Ambigaipalan, P. (2018) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-111317-095850 · Cited by 1,390 · cited 4×
“SDA is a metabolic intermediate in the transformation of α-ALA to EPA and DHA [26,27].”
BackgroundInfluentialHepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396 · cited 2×
“Compared to the previous research, our systematic review included seven more RCTs and provides the most updated research evidence [43,44,46,48,50,55,57].”
BackgroundResultLepretti, M., Martucciello, S., Burgos Aceves, M., Putti, R., & Lionetti, L. (2018) · Nutrients · doi:10.3390/nu10030350 · Cited by 232
Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
de Roos, B., Mavrommatis, Y., & Brouwer, I. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00189.x · Cited by 151 · cited 4×
“SDA is a metabolic intermediate in the transformation of α-ALA to EPA and DHA [26,27].”
BackgroundInfluential
Research works printed but not linked: 55
- Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 · DOI · Paper page
- Scorletti, 2014, Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the Welcome* study, Hepatology, 60, 1211, 10.1002/hep.27289 · DOI · Paper page
- Alkhouri, 2012, Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD, Gastroenterol. Hepatol., 8, 661
- McCullough, 2004, The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease, Clin. Liver Dis., 8, 521, 10.1016/j.cld.2004.04.004 · DOI · Paper page
- Adams, 2005, The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies, J. Hepatol., 42, 132, 10.1016/j.jhep.2004.09.012 · DOI · Paper page
- Pagadala, 2012, The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis, Clin. Liver Dis., 16, 487, 10.1016/j.cld.2012.05.006 · DOI
- Wong, 2010, Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years, Gut, 59, 969, 10.1136/gut.2009.205088 · DOI · Paper page
- Speliotes, 2010, Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The framingham heart study, Hepatology, 51, 1979, 10.1002/hep.23593 · DOI · Paper page
- Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C.D., and Targher, G. (2020). Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism, 154170. · DOI · Paper page
- Rinella, 2015, Nonalcoholic fatty liver disease: A systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 · DOI · Paper page
- Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati-Baroni, G., Valenti, L., and Bonino, F. (2016). Pathophysiology of non alcoholic fatty liver disease. Int. J. Mol. Sci., 17. · DOI · Paper page
- Haas, 2016, Pathophysiology and mechanisms of nonalcoholic fatty liver disease, Annu. Rev. Physiol., 78, 181, 10.1146/annurev-physiol-021115-105331 · DOI · Paper page
- Imamura, F., Micha, R., Wu, J.H., de Oliveira Otto, M.C., Otite, F.O., Abioye, A.I., and Mozaffarian, D. (2016). Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucose-insulin homeostasis: A systematic review and meta-analysis of randomised controlled feeding trials. PLoS Med., 13. · DOI · Paper page
- Maximos, 2015, The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease, Hepatology, 61, 153, 10.1002/hep.27395 · DOI · Paper page
- Ganz, 2013, Immune and inflammatory pathways in NASH, Hepatol. Int., 7, 771, 10.1007/s12072-013-9468-6 · DOI · Paper page
- Vonghia, 2013, Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis, Int. J. Mol. Sci., 14, 19867, 10.3390/ijms141019867 · DOI · Paper page
- Siriwardhana, 2012, Health benefits of n-3 polyunsaturated fatty acids: Eicosapentaenoic acid and docosahexaenoic acid, Adv. Food Nutr. Res., 65, 211, 10.1016/B978-0-12-416003-3.00013-5 · DOI · Paper page
- Leaf, 1988, Cardiovascular effects of n-3 fatty acids, N. Engl. J. Med., 318, 549, 10.1056/NEJM198803033180905 · DOI · Paper page
- Phillipson, 1985, Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia, N. Engl. J. Med., 312, 1210, 10.1056/NEJM198505093121902 · DOI · Paper page
- Yang, S.J., and Chi, C.C. (2019). Effects of fish oil supplement on psoriasis: A meta-analysis of randomized controlled trials. BMC Complement. Altern. Med., 19. · DOI
- Pahlavani, 2017, Adipose tissue inflammation in insulin resistance: Review of mechanisms mediating anti-inflammatory effects of omega-3 polyunsaturated fatty acids, J. Investig. Med., 65, 1021, 10.1136/jim-2017-000535 · DOI · Paper page
- Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American association for the study of liver diseases, American College of gastroenterology, and the American gastroenterological association, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI · Paper page
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, Open Med., 3, e123
- Follmann, 1992, Variance imputation for overviews of clinical trials with continuous response, J. Clin. Epidemiol., 45, 769, 10.1016/0895-4356(92)90054-Q · DOI · Paper page
- Higgins, J.P., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, Chichester Wiley.
- Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 18, d5928, 10.1136/bmj.d5928 · DOI · Paper page
- AlGhamdi, 2013, Methotrexate for the treatment of generalized vitiligo, Saudi. Pharm. J., 21, 423, 10.1016/j.jsps.2012.12.003 · doi:10.1016/j.jsps.2012.12.003
- Boyraz, 2015, Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease, J. Clin. Res. Pediatric Endocrinol., 7, 121, 10.4274/jcrpe.1749 · DOI · Paper page
- Dasarathy, 2015, Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis, J. Clin. Gastroenterol., 49, 137, 10.1097/MCG.0000000000000099 · DOI · Paper page
- Janczyk, 2015, Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: A randomized controlled trial, J. Pediatrics, 166, 1358, 10.1016/j.jpeds.2015.01.056 · DOI
- Li, 2016, Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis, World J. Gastroenterol., 22, 7008
- Moulder, 2013, RBC lipid composition is favorably altered in NASH patients treated with omega-3 fish oil versus placebo, Hepatology, 58, 499A
- Nogueira, 2016, Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial, Clin. Nutr., 35, 578, 10.1016/j.clnu.2015.05.001 · DOI
- Oscarsson, 2018, Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study, J. Clin. Lipidol., 12, 1390, 10.1016/j.jacl.2018.08.003 · DOI · Paper page
- Pacifico, 2015, A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease, Nutr. Metab. Cardiovasc. Dis. NMCD, 25, 734, 10.1016/j.numecd.2015.04.003 · DOI
- Parker, H.M., Cohn, J.S., O’Connor, H.T., Garg, M.L., Caterson, I.D., George, J., and Johnson, N.A. (2019). Effect of fish oil supplementation on hepatic and visceral fat in overweight men: A randomized controlled trial. Nutrients, 11. · DOI · Paper page
- Qin, Y., Zhou, Y., Chen, S.H., Zhao, X.L., Ran, L., Zeng, X.L., Wu, Y., Chen, J.L., Kang, C., and Shu, F.R. (2015). Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin E2 in nonalcoholic fatty liver disease associated with hyperlipidemia: A randomized clinical trial. PLoS ONE, 10. · DOI · Paper page
- Chen, 2008, Therapeutic efficacy of omega-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease, World Chin. J. Dig., 16, 2002, 10.11569/wcjd.v16.i18.2002 · DOI
- Sanyal, 2014, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial, Gastroenterology, 147, 377, 10.1053/j.gastro.2014.04.046 · DOI · Paper page
- Sofi, 2010, Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: A preliminary study, Int. J. Food Sci. Nutr., 61, 792, 10.3109/09637486.2010.487480 · DOI · Paper page
- Song, L., Zhao, X., Ouyang, P., Guan, Q., Yang, L., Peng, F., Du, H., Yin, F., Yan, W., and Yu, W. (2020). Combined effect of omega-3 fatty acids and phytosterol ester on alleviating hepatic steatosis in NAFLD subjects: A double-blind placebo-controlled clinical trial. Br. J. Nutr. · DOI
- Spadaro, 2008, Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease, Dig. Liver Dis., 40, 194, 10.1016/j.dld.2007.10.003 · DOI · Paper page
- Tobin, D., Brevik-Andersen, M., Qin, Y., Innes, J.K., and Calder, P.C. (2018). Evaluation of a high concentrate omega-3 for correcting the omega-3 fatty acid nutritional deficiency in non-alcoholic fatty liver disease (CONDIN). Nutrients, 10. · doi:10.20944/preprints201807.0240.v1
- Kong, X. (2011). A Basic and Clinical Reseach of ω-3 Polyunsaturated Fatty Acids to Seal Non-alcoholic Fatty Liver Disease. [Master‘s Thesis, Dalian Medical University].
- Zhu, 2008, Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia, World J. Gastroenterol., 14, 6395, 10.3748/wjg.14.6395 · DOI · Paper page
- Hu, 2015, Therapeutic effect of seal oil on non-alcoholic fatty liver disease, Acad. J. Guangzhou Med. Univ., 4, 31
- Hernaez, 2011, Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis, Hepatology, 54, 1082, 10.1002/hep.24452 · DOI · Paper page
- Saadeh, 2002, The utility of radiological imaging in nonalcoholic fatty liver disease, Gastroenterology, 123, 745, 10.1053/gast.2002.35354 · DOI · Paper page
- Guido, 2004, Liver biopsy sampling in chronic viral hepatitis, Semin. Liver Dis., 24, 89, 10.1055/s-2004-823103 · DOI · Paper page
- Tannapfel, 2010, Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease, Z. Gastroenterol., 48, 486, 10.1055/s-0029-1245278 · doi:10.1055/s-0029-1245278
- Marsman, 2011, Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model, J. Gastroenterol. Hepatol., 26, 356, 10.1111/j.1440-1746.2010.06326.x · DOI
- Yu, 2017, The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs, Pak. J. Med. Sci., 33, 1022, 10.12669/pjms.334.12315 · DOI · Paper page
- Zivkovic, 2007, Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease, Am. J. Clin. Nutr., 86, 285, 10.1093/ajcn/86.2.285 · DOI · Paper page
- Calder, 2013, Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?, Br. J. Clin. Pharmacol., 75, 645, 10.1111/j.1365-2125.2012.04374.x · DOI · Paper page
- Wall, 2010, Fatty acids from fish: The anti-inflammatory potential of long-chain omega-3 fatty acids, Nutr. Rev., 68, 280, 10.1111/j.1753-4887.2010.00287.x · DOI · Paper page
Cited by
Musazadeh, V., Karimi, A., Malekahmadi, M., Ahrabi, S. S., & Dehghan, P. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13750 · Cited by 44
Santos, H. O., & Penha-Silva, N. (2025) · Nutrition · doi:10.1016/j.nut.2024.112617 · Cited by 11
Li, L., Cong, C., Zhang, X., & Zhang, X. (2026) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s573711
Metadata
- Authors
- Lee, C.-H., Fu, Y., Yang, S.-J., & Chi, C.-C.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-09-11
- Volume
- 12
- Issue
- 9
- Pages
- 2769
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3085538111
- Cited by
- 139
- References
- 16
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.